This blog is a collection of my favorite new treatments for lung cancer currently available through clinical trials. The start of each post contains a brief description of the approach, reasons I included it and a link to the trial website.

Dacomitinib For EGFR Inhibitor Resistant NSCLC`s

Dacomitinib is one of the latest advances in treatment of EGFR mutant NSCLC’s that have become resistant to reversible EGFR tyrosine kinase inhibitors. Dacomitinib differs from other EGFR inhibitors in that it irreversibly inhibits EGFR, HER2 and… [Learn More…]

Adjunct TG4010 for Advanced Non-Small Cell Lung Cancer (NSCLC)

TG4010 (MVA-MUC1-IL2) is a poxvirus vector that has been adapted to target MUC1, which is a major tumor-associated antigen. MVA is a highly attenuated (non-pathogenic) strain, which has been tested extensively in humans as a smallpox vaccine and is… [Learn More…]

Why All Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Should Have Their Tumors Tested for EGFR and ALK Abnormalities

The anaplastic lymphoma kinase (ALK) fusion oncogene and the epidermal growth factor receptor (EGFR) represent molecular targets in a subset of non-small cell lung cancers (NSCLCs). NSCLC accounts for nearly 85 % of all lung cancers with 7 % of… [Learn More…]

Cetuximab and Chemoradiation Therapy Significantly Improves Overall Survival of Patients with Unresectable Stage III NSCLC

Non-small cell lung cancers (NSCLC) commonly express the epidermal growth factor receptor (EGFR), which is associated with poor clinical outcome. Cetuximab is an inhibitor of EGFR and has radio-sensitization properties. In this study of patients… [Learn More…]